CACLP - The largest IVD Expo & Conference

YZY Biopharma Received 200 Million CNY in Financing to Accelerate Research and Development of COVID-19 Vaccine

Industry news | 06 July, 2022 | CACLP

Recently, Wuhan YZY Biopharma Co., Ltd completed a 200 million CNY Pre-C round of financing. This round of financing was completed by the joint investment of Wuhan Hi-Tech, Hubei Science Technology Investment and Optics Valley Financial Holding Group. Funds will be used for clinical research and development of product pipelines including dual antibodies and COVID-19 vaccine, and to accelerate product launch.


Product R&D



At present, YZY Biopharma has 5 clinical and multiple pre-clinical pipeline products under development, covering multiple disease fields such as oncology, ophthalmology, and COVID-19.

 

M701 is the first antibody drug targeting EpCAM/CD3 in the clinic. It can specifically bind to EpCAM-positive tumor cells, and at the same time bind to the T cell surface antigen CD3, recruit and activate T cells to kill tumor cells, and its main indications are EpCAM-positive tumors malignant ascites/pleural effusion. The clinical phase I of M701 has been completed, and the interim research results of phase I clinical trial have been published on the ESMO official website, showing good safety, tolerability and efficacy. The product is currently undergoing phase II clinical research.

 

Y2019 COVID-19 vaccine combines design research results of Wuhan Institute of Virology, Chinese Academy of Sciences and the advantages of YZY Biopharma recombinant protein industrialization platform, and has advantages in product quality control and large-scale production. Y2019 vaccine has good stability at room temperature and 4°C, and can be quickly produced in large-scale production. At present, the vaccine is being carried out in the phase I clinical study of the adult group and the elderly group by Hubei Center for Disease Control and Prevention. The preliminary results show that the vaccine is safe, and further phase II clinical studies will be carried out in near future.


Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference